331 related articles for article (PubMed ID: 25030312)
21. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
22. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
Chung EJ; Kim JH; Ahn HS; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
25. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.
Futamura Y; Asami T; Nonobe N; Kachi S; Ito Y; Sato Y; Hayakawa M; Terasaki H
Jpn J Ophthalmol; 2015 Nov; 59(6):378-88. PubMed ID: 26265249
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
Hartnett ME
Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity.
Minturn R; Hartigan K; Vegunta S; Boente C; Golzarri-Arroyo L; Hynes E; Laughlin E; Haider K; Kua KL
BMC Ophthalmol; 2024 May; 24(1):220. PubMed ID: 38790043
[TBL] [Abstract][Full Text] [Related]
28. [VEGF antibodies as therapy for retinopathy of prematurity].
Oberacher-Velten IM; Helbig H
Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
[TBL] [Abstract][Full Text] [Related]
29. Confluent diode laser coagulation: the gold standard of therapy for retinopathy of prematurity.
Prepiaková Z; Tomcíková D; Kostolná B; Gerinec A
J Pediatr Ophthalmol Strabismus; 2015; 52(1):43-51. PubMed ID: 25643370
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
Flavahan PW; Lavy TE; Wykes W
Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
33. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
34. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
Dikci S; Ceylan OM; Demirel S; Yılmaz T
Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
[TBL] [Abstract][Full Text] [Related]
35. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
[TBL] [Abstract][Full Text] [Related]
36. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
[TBL] [Abstract][Full Text] [Related]
37. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
VanderVeen DK; Cataltepe SU
Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
[TBL] [Abstract][Full Text] [Related]
38. A Comparison of Respiratory Outcomes after Treating Retinopathy of Prematurity with Laser Photocoagulation or Intravitreal Bevacizumab.
Barry GP; Tauber KA; Greenberg S; Lajoie J; Afroze F; Oechsner H; Finucane E; Binenbaum G
Ophthalmol Retina; 2020 Dec; 4(12):1202-1208. PubMed ID: 32512055
[TBL] [Abstract][Full Text] [Related]
39. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.
Ittiara S; Blair MP; Shapiro MJ; Lichtenstein SJ
J AAPOS; 2013 Jun; 17(3):323-5. PubMed ID: 23607977
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
